AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21969495 — intervention group
Group type: COMPARATOR
Intervention: CAP (825 mg/m2 orally twice daily, days 1 to 14)
Number of subjects: 38
Study 21969495 — intervention group
Group type: EXPERIMENTAL
Intervention: P-CAP (subset analysis of fluorouracil-refractory patients)
Number of subjects: 38
Study 21969495 — intervention group
Group type: COMPARATOR
Intervention: CAP (subset analysis of fluorouracil-refractory patients)
Number of subjects: 38
Study 18819175 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (prophylactic agent) with an Active Response Rate (ARR) of 50%
Number of subjects: 270
Study 18819175 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with a Placebo Response Rate (PRR) of 25%
Number of subjects: 270
Study 16918593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (INH) administered preprandially using a metered-dose inhaler (MDI) for 4 weeks
Number of subjects: 24
Study 16918593 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GLA) injected subcutaneously at bedtime for 4 weeks
Number of subjects: 24
Study 12600857 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-methyltetrahydrofolate (113 microg)
Number of subjects: 167
Study 12600857 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (100 microg)
Number of subjects: 167
Study 12600857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 10987607 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous isosorbide-dinitrate (ISDN) 4 mg every 4 min (n = 20)
Number of subjects: 40
Study 10987607 — intervention group
Group type: COMPARATOR
Intervention: BiPAP ventilation and standard dose nitrate therapy (n = 20)
Number of subjects: 40
Study 8617895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 200
Study 8617895 — intervention group
Group type: COMPARATOR
Intervention: Computerized balance training (BT)
Number of subjects: 200
Study 8617895 — intervention group
Group type: COMPARATOR
Intervention: Education (ED)
Number of subjects: 200
Study 1333903 — intervention group
Group type: EXPERIMENTAL
Intervention: L-TAE with Farmorubicin (FARM)
Number of subjects: 117
Study 1333903 — intervention group
Group type: COMPARATOR
Intervention: L-TAE with Adriamycin (ADR)
Number of subjects: 117
Study 6711269 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml of 0.5% mepivacaine with adrenaline (200 mg)
Number of subjects: 90
Study 6711269 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml of 1% mepivacaine with adrenaline (400 mg)
Number of subjects: 90
Study 6711269 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml of 1.5% mepivacaine with adrenaline (600 mg)
Number of subjects: 90
Study 6711269 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 90
Study 31162191 — intervention group
Group type: EXPERIMENTAL
Intervention: XueBiJing injection (100 mL, q12 hours)
Number of subjects: 710
Study 31162191 — intervention group
Group type: EXPERIMENTAL
Intervention: XueBiJing injection
Number of subjects: 710
Study 31162191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 28750059 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Number of subjects: 187
Study 28750059 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of reduced-glycerin 1% tenofovir (RG-TFV) gel
Number of subjects: 187
Study 28750059 — intervention group
Group type: EXPERIMENTAL
Intervention: RG-TFV gel applied before and after receptive anal intercourse (RAI)
Number of subjects: 187
Study 28750059 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence measurement
Number of subjects: 187
Study 28750059 — intervention group
Group type: EXPERIMENTAL
Intervention: Product PK results
Number of subjects: 187
Study 24906790 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Remediation (FR), n=17
Number of subjects: 53
Study 24906790 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PSY), n=19
Number of subjects: 53
Study 24906790 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU), n=17
Number of subjects: 53
Study 24282626 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (10 mg/kg/day in a single dose for 7 days)
Number of subjects: 627
Study 24282626 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (20 mg/kg/day in two divided doses for 7 days)
Number of subjects: 627
Study 21954644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g i.v. 3 times a day and amikacine 500 mg i.v. 2 times a day (Group 1A)
Number of subjects: 40
Study 21954644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g i.v. bolus, then permanent infusion 3 g per day and amikacine 15 mg/kg per day once a day (Group 1B)
Number of subjects: 40
Study 19700988 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA (0.1% bupivacaine plus hydromorphone 10 mcg/mL at 8 mL/h plus bolus dosing)
Number of subjects: 38
Study 19700988 — intervention group
Group type: COMPARATOR
Intervention: IV‐PCA (hydromorphone 2 mcg/kg/h continuous infusion; 2 mcg/kg bolus dose)
Number of subjects: 38
Study 16916874 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chloramphenicol and 1% clotrimazole ointment
Number of subjects: 374
Study 16916874 — intervention group
Group type: COMPARATOR
Intervention: 1% chloramphenicol and placebo ointment
Number of subjects: 374
Study 15675184 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF plasmid DNA (three dose/regimens)
Number of subjects: 100
Study 15675184 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study 11563497 — intervention group
Group type: EXPERIMENTAL
Intervention: Incandescent WALK sign
Number of subjects: 0
Study 11563497 — intervention group
Group type: EXPERIMENTAL
Intervention: White LED WALK sign
Number of subjects: 0
Study 11563497 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue LED WALK sign
Number of subjects: 0
Study 11563497 — intervention group
Group type: EXPERIMENTAL
Intervention: White LED WALK sign with animated 'eyes' display
Number of subjects: 0
Study 11563497 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue LED WALK sign with animated 'eyes' display
Number of subjects: 0
Study 11563497 — intervention group
Group type: EXPERIMENTAL
Intervention: Incandescent WALK sign with animated 'eyes' display
Number of subjects: 0
Study 11563497 — intervention group
Group type: COMPARATOR
Intervention: Control group (signals without animated 'eyes' display)
Number of subjects: 0
Study 9425843 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole in the night before operation
Number of subjects: 50
Study 9425843 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive lansoprazole)
Number of subjects: 50
Study 8484550 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous supplemental inspired oxygen by nasal catheters [4 L/min] (Oxygen Group, n = 52)
Number of subjects: 104
Study 8484550 — intervention group
Group type: COMPARATOR
Intervention: No supplemental inspired oxygen (Control Group, n = 52)
Number of subjects: 104
Study 8484550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Oxygen Group and Control Group)
Number of subjects: 104
Study 3318443 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1,200 mg per day
Number of subjects: 45
Study 3318443 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg per day
Number of subjects: 45
Study 3318443 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 45
Study 3318443 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 45
Study 30375301 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who never relapsed (21% of 178 patients)
Number of subjects: 178
Study 30375301 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate predictors of non-relapse
Number of subjects: 178
Study 30375301 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis
Number of subjects: 178
Study 29042390 — intervention group
Group type: EXPERIMENTAL
Intervention: POC culture and susceptibility testing (Flexicult SSI‐Urinary Kit)
Number of subjects: 191
Study 29042390 — intervention group
Group type: COMPARATOR
Intervention: POC culture only (ID Flexicult)
Number of subjects: 191
Study 29042390 — intervention group
Group type: EXPERIMENTAL
Intervention: POC culture and susceptibility testing
Number of subjects: 191
Study 29042390 — intervention group
Group type: COMPARATOR
Intervention: POC culture only
Number of subjects: 191
Study 26100719 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus text messages timed to medication regimen
Number of subjects: 75
Study 26100719 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study 23925738 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 82
Study 23925738 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 82
Study 22189640 — intervention group
Group type: EXPERIMENTAL
Intervention: AdperScotchbond Multi‐Purpose + resin cement RelyX ARC (SBMP+ARC)
Number of subjects: 48
Study 22189640 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper SingleBond 2 + RelyX ARC (SB+ARC)
Number of subjects: 48
Study 22189640 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX U100 self‐adhesive resin cement (U100)
Number of subjects: 48
Study 19663111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-BP 2.5% gel
Number of subjects: 2813
Study 19663111 — intervention group
Group type: COMPARATOR
Intervention: Active ingredients (clindamycin or benzoyl peroxide)
Number of subjects: 2813
Study 19663111 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 2813
Study 16831503 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CPR training plus specific tuition on the characteristics of agonal breathing
Number of subjects: 64
Study 16831503 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR training
Number of subjects: 64
Study 15488357 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail marketing pieces encouraging influenza vaccinations
Number of subjects: 339220
Study 15488357 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail marketing pieces encouraging pneumonia vaccinations
Number of subjects: 339220
Study 15488357 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail marketing pieces encouraging influenza/pneumonia vaccinations
Number of subjects: 339220
Study 12324782 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate
Number of subjects: 177
Study 12324782 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate and amoxicillin plus clavulanic acid
Number of subjects: 177
Study 12324782 — intervention group
Group type: COMPARATOR
Intervention: 0.09% sterile saline solution
Number of subjects: 177
Study 9502027 — intervention group
Group type: EXPERIMENTAL
Intervention: VENTEX Wound Dressing System (VWDS)
Number of subjects: 10
Study 9502027 — intervention group
Group type: COMPARATOR
Intervention: Xeroform gauze
Number of subjects: 10
Study 7636904 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization and maintenance of gastric mucosal pH (pHi) at or above 7.30
Number of subjects: 27
Study 7636904 — intervention group
Group type: COMPARATOR
Intervention: Maintaining Oxygen Delivery Index (DO2I) of 600 and Oxygen Consumption Index (VO2I) of > 150
Number of subjects: 27
Study 2702897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 78
Study 2702897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education plus social learning intervention
Number of subjects: 78
Study 2702897 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 78
Study 580055 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 2821 (40 mg)
Number of subjects: 0
Study 580055 — intervention group
Group type: COMPARATOR
Intervention: Etacrynic acid (50 mg)
Number of subjects: 0
Study 31012375 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE® program
Number of subjects: 39
Study 31012375 — intervention group
Group type: COMPARATOR
Intervention: Control group intervention
Number of subjects: 39
Study 28962635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 528
Study 28962635 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or best available therapy)
Number of subjects: 528
Study 28962635 — intervention group
Group type: COMPARATOR
Intervention: Control (censored at crossover)
Number of subjects: 528
Study 26126064 — intervention group
Group type: EXPERIMENTAL
Intervention: PURAP liquid-based pad
Number of subjects: 22
Study 23964830 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tadalafil on alternate days
Number of subjects: 200
Study 23964830 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of statin a day
Number of subjects: 200
Study 23964830 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tadalafil on alternate days and 10 mg of statin a day
Number of subjects: 200
Study 23964830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 200
Study 22668797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 500 mg administered intravenously twice weekly
Number of subjects: 29
Study 22668797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg administered intravenously twice weekly
Number of subjects: 29
Study 22668797 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both doses)
Number of subjects: 29
Study 22668797 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall αvβ3 expression
Number of subjects: 29
Study 19323964 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Therapy (RPT)
Number of subjects: 81
Study 19323964 — intervention group
Group type: COMPARATOR
Intervention: Standardized Case Management
Number of subjects: 81
Study 17298495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft + Ti-Mesh
Number of subjects: 23
Study 17298495 — intervention group
Group type: COMPARATOR
Intervention: Bone graft alone
Number of subjects: 23
Study 15388612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dogs trained to identify bladder cancer urine samples
Number of subjects: 144
Study 15388612 — intervention group
Group type: COMPARATOR
Intervention: Expected value of chance selection (1 in 7 or 14%)
Number of subjects: 144
Study 11172529 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-related pathways through medical illness
Number of subjects: 0
Study 11172529 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological, psychological, and psychosocial theories
Number of subjects: 0
Study 9680665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraphen
Number of subjects: 0
Study 9680665 — intervention group
Group type: COMPARATOR
Intervention: Phenyl-Free
Number of subjects: 0
Study 9680665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Tetraphen and Phenyl-Free
Number of subjects: 0
Study 8004312 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 18
Study 8004312 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Inverse Ratio Ventilation (VC-IRV)
Number of subjects: 18
Study 30350870 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made toothbrush
Number of subjects: 30
Study 30350870 — intervention group
Group type: COMPARATOR
Intervention: Normal toothbrush
Number of subjects: 30
Study 27570090 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 3319
Study 27570090 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3319
Study 24274627 — intervention group
Group type: EXPERIMENTAL
Intervention: supportive-expressive psychotherapy
Number of subjects: 149
Study 24274627 — intervention group
Group type: EXPERIMENTAL
Intervention: clinical management combined with pharmacotherapy
Number of subjects: 149
Study 24274627 — intervention group
Group type: EXPERIMENTAL
Intervention: clinical management combined with placebo
Number of subjects: 149
Study 24274627 — intervention group
Group type: EXPERIMENTAL
Intervention: alliance
Number of subjects: 149
Study 24274627 — intervention group
Group type: COMPARATOR
Intervention: No treatment differences
Number of subjects: 149
Study 22644636 — intervention group
Group type: EXPERIMENTAL
Intervention: Early LH exposure (recombinant LH 150 IU/day from day 1)
Number of subjects: 530
Study 22644636 — intervention group
Group type: COMPARATOR
Intervention: Late LH exposure (recombinant LH 150 IU/day from day 7)
Number of subjects: 530
Study 20686612 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive testing using a robotic linkage that passively moved the hand to each judgement location.
Number of subjects: 0
Study 20686612 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive testing with a persistent visual reference position.
Number of subjects: 0
Study 18693158 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl aminolaevulinate (MAL PDT)
Number of subjects: 118
Study 18693158 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 118
Study 16725264 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine granules (0.5 g/kg/d for 14 days)
Number of subjects: 48
Study 16725264 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine granules
Number of subjects: 48
Study 16725264 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo - glycine)
Number of subjects: 48
Study 14609903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose and oral tactile stimulation (with a pacifier or a bottle) and parental holding during immunization
Number of subjects: 116
Study 14609903 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (no sucrose or tactile stimulation)
Number of subjects: 116
Study 11340889 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated static threshold perimetry on Humphery visual field (HVF) analyzer
Number of subjects: 54
Study 11340889 — intervention group
Group type: COMPARATOR
Intervention: Manual suprathreshold perimetry on Goldmann perimeter
Number of subjects: 54
Study 8993082 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused psychoeducational treatment
Number of subjects: 0
Study 8993082 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual, interpersonally-oriented psychotherapy
Number of subjects: 0
Study 1511309 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial load
Number of subjects: 10
Study 1511309 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring load
Number of subjects: 10
Study 1511309 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretched-spring load
Number of subjects: 10
Study 6143471 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (hydrochlorothiazide)
Number of subjects: 47
Study 6143471 — intervention group
Group type: COMPARATOR
Intervention: Beta-adrenoceptor blocker (metoprolol)
Number of subjects: 47
Study 6143471 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (in 6 patients)
Number of subjects: 47
Study 30156171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist PPRA group
Number of subjects: 610
Study 30156171 — intervention group
Group type: COMPARATOR
Intervention: Fellow PPRA group
Number of subjects: 610
Study 26797117 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered problem-solving training (PST)
Number of subjects: 80
Study 23535984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intensive care follow-up programme
Number of subjects: 286
Study 23535984 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 286
Study 22906847 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 20
Study 22906847 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 20
Study 20739445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement containing (n-3) fatty acids (2.0 g EPA + 0.9 g DHA/d)
Number of subjects: 40
Study 18631272 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 542
Study 18631272 — intervention group
Group type: COMPARATOR
Intervention: CRT-P
Number of subjects: 542
Study 18631272 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 542
Study 18631272 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D device
Number of subjects: 542
Study 18631272 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure
Number of subjects: 542
Study 18631272 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 542
Study 18631272 — intervention group
Group type: EXPERIMENTAL
Intervention: History of atrial fibrillation
Number of subjects: 542
Study 15705052 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g.d(‐1) x 5 d)
Number of subjects: 0
Study 15705052 — intervention group
Group type: COMPARATOR
Intervention: Glucose placebo (PL)
Number of subjects: 0
Study 12885709 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phytate bread fortified with zinc sulfate (60 mg elemental Zn/kg wheat flour)
Number of subjects: 22
Study 12885709 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-phytate porridge fortified with zinc sulfate (60 mg elemental Zn/kg wheat flour)
Number of subjects: 22
Study 12885709 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-phytate porridge fortified with zinc oxide (60 mg elemental Zn/kg wheat flour)
Number of subjects: 22
Study 12885709 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-phytate porridge with additional test meal fortified with zinc oxide and labeled with (65)ZnCl(2)
Number of subjects: 22
Study 10673885 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen 3 litre min‐1 before sevoflurane
Number of subjects: 28
Study 10673885 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen 6 litre min‐1 before sevoflurane
Number of subjects: 28
Study 10673885 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rebreathing group (sevoflurane in oxygen 6 litre min‐1 from the start)
Number of subjects: 28
Study 8671370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium group
Number of subjects: 18
Study 8671370 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium group
Number of subjects: 18
Study 8671370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18